Home / Health / New PsA Drugs Poised to Reshape Treatment
New PsA Drugs Poised to Reshape Treatment
15 May
Summary
- Icotyde, an oral IL-23 pill, shows promise but may be slow-acting for highly active PsA.
- Sonelokimab, an IL-17A/F blocker, faces competition and needs to prove differentiation.
- SPY072 offers a novel TL1A mechanism with potential dual anti-fibrotic benefits.
The upcoming European Alliance of Associations for Rheumatology (EULAR) 2026 meeting will highlight advancements in psoriatic arthritis (PsA) treatment. Johnson & Johnson's oral Icotyde, an IL-23 inhibitor, has received US approval for plaque psoriasis and is undergoing late-stage trials for PsA. While viewed as a potential new option, its slow-acting nature might limit its use for patients needing immediate relief.
MoonLake Therapeutics is developing sonelokimab, an IL-17A and IL-17F blocker, for PsA. This subcutaneous therapy is in Phase III trials and aims to rival existing treatments like bimekizumab. However, it must demonstrate clear efficacy or cost advantages to gain market share.
Spyre Therapeutics is investigating SPY072, an anti-TL1A antibody, which targets a novel mechanism distinct from current IL blockers. This therapy aims to suppress immune response and potentially prevent fibrosis, offering a unique dual benefit.
These emerging therapies, including Icotyde, sonelokimab, and SPY072, represent potential shifts in PsA management. Physicians are particularly interested in novel mechanisms and long-term disease benefits, suggesting these new agents could significantly impact patient care moving forward.
